Understand the source comparison
Peptides for SIBO Compared: Systemic vs Local Effects
BPC-157 Angiogenesis + collagen synthesis Moderate. Promotes healing in multiple tissues High. Restores tight junctions, reduces mucosal lesions Strong (multiple animal studies, limited human data) Best barrier-repair peptide with systemic healing benefits KPV
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Angiogenesis + collagen synthesis
- Moderate. Promotes healing in multiple tissues
- High. Restores tight junctions, reduces mucosal lesions
- Strong (multiple animal studies, limited human data)
- Best barrier-repair peptide with systemic healing benefits
- KPV
- NF-κB inhibition
- Low. Rapid enzymatic degradation limits systemic duration
- High. Direct anti-inflammatory action at mucosal surface
- Moderate (Phase 2 human trial in IBD, no SIBO-specific RCTs)
- Most targeted immune modulator for gut inflammation
- LL-37
- Antimicrobial membrane disruption
- Moderate. Endotoxin neutralisation reduces systemic LPS burden
- High. Selective bacterial killing without resistance
- Strong (extensive antimicrobial research, limited gut-specific dosing protocols)
- Only peptide with direct antimicrobial action studied in gut models
- Thymosin Beta-4
- Actin sequestration + cell migration
- High. Wound healing across tissues
- Moderate. Promotes epithelial cell migration but less gut-specific data than BPC-157
- Moderate (wound healing data robust, gut barrier applications emerging)
- Broader tissue repair peptide with less SIBO-specific research
- BPC-157's systemic effects extend beyond the gut. Studies show accelerated tendon healing, reduced muscle damage from corticosteroid use, and neuroprotective effects in brain injury models. For SIBO applications, this systemic reach means subcutaneous BPC-157 administered remotely from the abdomen still reaches intestinal tissue through circulation. The peptide's stability in gastric juice also allows oral administration with some efficacy, though absorption rates are lower than injection. Most research protocols use subcutaneous injection to ensure consistent dosing.
- KPV's rapid enzymatic breakdown limits systemic duration. Plasma half-life is under 30 minutes. But that's actually advantageous for gut-targeted therapy. When delivered orally with enteric protection, KPV reaches the inflamed intestinal mucosa at high local concentrations without prolonged systemic immunosuppression. This is critical in SIBO contexts where the goal is reducing mucosal inflammation (which drives permeability and bacterial translocation) without compromising the immune system's ability to clear translocated bacteria. KPV modulates the inflammatory response rather than suppressing it.
- LL-37's systemic antimicrobial effects include neutralisation of bacterial endotoxins (LPS) that enter circulation through a leaky gut. A 2020 Cell Host & Microbe study found that LL-37 binds LPS and prevents it from activating TLR4 receptors on immune cells. Reducing systemic inflammation driven by bacterial translocation. For SIBO patients, this means LL-37 doesn't just reduce bacterial overgrowth locally; it also mitigates the endotoxemia that drives brain fog, fatigue, and systemic inflammatory symptoms commonly attributed to SIBO.